Skip to Content
Search Menu

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

New treatment option provides hope for patients with endocrine-resistant HR+/HER2- metastatic breast cancer, who until today have had very limited treatment options.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

CAR-T Will Transform the Treatment of Malignant Diseases, But Challenges Remain in Selection, Logistics, and Toxicity

/ Julian Hamfjord / Jan Andreasen
CancerCAR-T

ESMO 2024: Presentations and Perspectives of New Data at Norwegian Evening

/ BestPractice Nordic
CancerESMO24

ESMO 2024: Presentations and Perspectives of New Data at Danish Evening

/ Jan Andreasen
CancerESMO24

Enhancing Quality of Life in Cancer Patients and Survivors Through Behavioral Graded Activity and Psychological Therapy

/ Astrid Lahousse
CancerQuality of life
Live Fagereng

Necessary to Evaluate and Justify Off-Label Use of Oncology Drugs to Provide Equal Access to Effective Treatment

/ Live Fagereng
CancerESMO24 Play the Video 2:06
Martin Højgaard

Durable Responses and Stable Disease in Multiple ATM-Altered Advanced Cancers

/ Martin Højgaard
CancerESMO24 Play the Video 09:40

Physical Activity, Fitness, and Cardiovascular Disease Risk in Adolescent Cancer Survivors

/ Mari Bratteteig / Corina S. Rueegg / May Grydeland / Sigmund A. Anderssen / Ellen Ruud
CancerCardiovascular diseaseChildrenExercise
Christina H. Ruhlmann

Updated MASCC/ESMO Guidelines on Prevention of Cancer Therapy-Induced Nausea and Vomiting

/ Christina H. Ruhlmann
CancerChemotherapyTreatment Play the Video 7:41
Luca Incrocci

Is There a Sexual Life After Cancer?

/ Luca Incrocci
Cancer Play the Video 1:49
Back to top